publication date: Jan. 2, 2015

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

 

Premenopausal women who received ovarian suppression treatment along with tamoxifen had a lower risk of breast cancer recurrence, according to data from a clinical trial sponsored and supported by NCI.

The study showed that suppressing ovarian function reduced breast cancer recurrence in premenopausal women receiving the drug tamoxifen after surgery for early-stage breast cancer.

The phase III trial, SOFT (Suppression of Ovarian Function Trial), used either monthly injections of the drug triptorelin, surgical removal of both ovaries, or radiation of the ovaries as methods of ovarian suppression in women with hormone receptor-positive breast cancer.

Women in the trial were randomly assigned to treatment with tamoxifen alone for five years, treatment with tamoxifen plus ovarian suppression for five years, or treatment with exemestane plus ovarian suppression for five years. Exemestane inhibits aromatase, an enzyme necessary for the production of estrogen.

The International Breast Cancer Study Group, which received support and funding from NCI, presented the results at the San Antonio Breast Cancer Symposium. The results were also published in the New England Journal of Medicine.

Researchers studied the three treatments in two different groups of premenopausal women with early-stage, hormone receptor-positive breast cancer: those who had received chemotherapy post-surgery and those who had not. Only women who remained premenopausal after chemotherapy were included in the trial.

Treatment with tamoxifen plus ovarian suppression reduced the relative risk of breast cancer recurrence by 22 percent in women who had received chemotherapy compared to treatment with tamoxifen alone. Treatment with exemestane plus ovarian suppression reduced the relative risk of breast cancer recurrence in chemotherapy-treated patients by 35 percent compared to … Continue reading CCL Dec – Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.